NCT06001671View on ClinicalTrials.gov

Antitumor Activity and Safety of BEBT-109, a Novel EGFR Inhibitor, in Previously Treated NSCLC

PHASE1CompletedINTERVENTIONAL
Enrollment

23

Participants

Timeline

Start Date

October 27, 2020

Primary Completion Date

March 1, 2023

Study Completion Date

August 8, 2023

Conditions
NSCLC
Interventions
DRUG

BEBT-109

"BEBT-109 is based on the 3+3 model, with a dose ascent starting from 120mg qd"

Trial Locations (1)

Unknown

Hunan Cancer hospital, Changsha

All Listed Sponsors
lead

Hunan Province Tumor Hospital

OTHER

NCT06001671 - Antitumor Activity and Safety of BEBT-109, a Novel EGFR Inhibitor, in Previously Treated NSCLC | Biotech Hunter | Biotech Hunter